La cadena de opciones muestra datos clave de las opciones de acciones de Prothena Corp a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Prothena Corp..

Prothena Corp (NASDAQ:PRTA) Bolsa, Cadena de Opciones

Prothena Corp

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

New,York,,Usa,-,January,07,,2025:,E2open,Website,Displayed

ABEO

BLMZ

CMBM

DGLY

DGNX

ETWO

GORV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IMNN

IXHL

ONCY

PMAX

PRTA

SBET

SILO

VVPR

WORX

Consulta las acciones con mayores subidas y caídas en el premercado estadounidense de hoy, incluyendo tecnológicas, biotecnológicas y más.

Las acciones de E2open se disparan un 25%; aquí están 20 acciones que se mueven en el premercado

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Across the recent three months, 8 analysts have shared their insights on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.75, a high estimate of $81.00, and a low estimate of $4.00. This current average has decreased by 34.38% from the previous average price target of $56.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750428030_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Prothena Corp is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Prothena Corp's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Prothena Corp</h2>
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
<h3>Financial Insights: Prothena Corp</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Prothena Corp displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 5556.0%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -2128.54%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Prothena Corp's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.02%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Prothena Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

8 Analysts Assess Prothena Corp: What You Need To Know

Cantor Fitzgerald analyst Eric Schmidt reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from Neutral to Neutral.

News

Reiteration

Cantor Fitzgerald Reiterates Neutral on Prothena Corpto Neutral

Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) today announced that the Company has initiated an approximate 63% reduction in its workforce to substantially reduce its operating costs to those necessary to support its remaining wholly owned programs, its obligations to partnered programs, and its anticipated business development activities.
 &nbsp;

Guidance

Prothena Cuts Workforce By ~63% To Streamline Operations And Reduce Costs; Revises FY25 Financial Guidance

WIIM

Prothena shares are trading higher after the company annoucned its partner, Roche, will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's disease.

Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) today announced partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLE) from both PADOVA and the Phase II PASADENA study.
"As pioneers in developing the first anti-alpha-synuclein targeting antibody, we are excited to see Roche advancing prasinezumab into Phase III development, with the potential to deliver the first disease-modifying treatment option to the millions of individuals living with Parkinson's disease and their families," stated Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.
Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks (two years) were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology.
The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease, are ongoing.

Prothena and Roche Move Parkinson's Drug to Phase III in Bid for First Disease-Modifying Treatment

B of A Securities analyst Tazeen Ahmad downgrades Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from Neutral to Underperform and lowers the price target from $22 to $4.

Downgrades

Price Target

B of A Securities Downgrades Prothena Corp to Underperform, Lowers Price Target to $4

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) price target from $115 to $125. Needham analyst Mike Cikos maintained a Buy rating. Okta shares closed at $125.50 on Tuesday. See how other<a href="https://www.benzinga.com/quote/OKTA/analyst-ratings"> analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised the price target for Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) from $180 to $195. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Franco-Nevada shares closed at $168.24 on Tuesday. <a href="https://www.benzinga.com/quote/FNV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut Rocket Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) price target from $29 to $2.5. Jefferies analyst Andrew Tsai downgraded the stock from Buy to Hold. Rocket Pharmaceuticals shares closed at $2.33 on Tuesday. <a href="https://www.benzinga.com/quote/RCKT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo increased the price target for Barings BDC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDC#NYSE">BBDC</a>) from $8.5 to $9.5. Wells Fargo analyst Finian O&#8217;Shea upgraded the stock from Equal-Weight to Overweight. Barings BDC shares closed at $9.24 on Tuesday. <a href="https://www.benzinga.com/quote/bbdc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Runway Growth Finance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) from $10 to $9.5. Wells Fargo analyst Finian O&#8217;Shea downgraded the stock from Overweight to Equal-Weight. Runway Growth Finance shares closed at $9.83 on Tuesday. See how <a href="https://www.benzinga.com/quote/RWAY/analyst-ratings">other analysts view this stock</a>.</li>
<li>D. Boral Capital cut CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) price target from $14 to $12. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. CollPlant Biotechnologies shares settled at $1.93 on Tuesday. <a href="https://www.benzinga.com/quote/CLGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Bridger Aerospace Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) price target from $5 to $5.25. Canaccord Genuity analyst Austin Moeller maintained a Buy rating. Bridger Aerospace shares closed at $1.37 on Tuesday. <a href="https://www.benzinga.com/quote/BAER/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) price target from $400 to $350. Canaccord Genuity analyst David Hynes maintained a Buy rating. Salesforce shares closed at $277.19 on Tuesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from $7 to $6. Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating. Sunrun shares settled at $7.19 on Tuesday. <a href="https://www.benzinga.com/quote/RUN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised The Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) price target from $64 to $67. Wells Fargo analyst Praneeth Satish maintained an Overweight rating. Williams Companies shares closed at $60.10 on Tuesday. <a href="https://www.benzinga.com/quote/WMB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying OKTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-1024x585.png" alt="" class="wp-image-929866" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

BAER

BBDC

CLGN

OKTA

PTCT

RCKT

RWAY

Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares rose 60.0% to $0.64 during Tuesday's regular session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock rose 40.28% to $11.91. The market value of their outstanding shares is at $78.4 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 29.08% to $37.34. The company's market cap stands at $273.5 million. </li>
<li>Anteris Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) stock increased by 27.19% to $4.63. The company's market cap stands at $166.4 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares moved upwards by 24.24% to $0.93. The company's market cap stands at $111.5 million. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares rose 24.05% to $2.63. The market value of their outstanding shares is at $90.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) shares decreased by 61.9% to $2.39 during Tuesday's regular session. The company's market cap stands at $257.2 million. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares declined by 34.0% to $11.67. The company's market cap stands at $382.7 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) stock fell 30.95% to $4.54. The company's market cap stands at $244.5 million. </li>
<li>Savara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) stock decreased by 30.64% to $1.97. The market value of their outstanding shares is at $340.4 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) shares declined by 26.31% to $10.98. The market value of their outstanding shares is at $91.8 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock fell 20.01% to $0.98. The market value of their outstanding shares is at $130.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

EXOZ

FBRX

IVVD

NOTV

NPCE

RAPT

SVRA

TNXP

12 Health Care Stocks Moving In Tuesday's Intraday Session

Oppenheimer analyst Jay Olson downgrades Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from Outperform to Perform.

Oppenheimer Downgrades Prothena Corp to Perform

Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Overweight and lowers the price target from $110 to $81.

Piper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $81

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Ascendiant Capital raised Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) price target from $54 to $56. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares closed at $46.24 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. slashed the price target for Unity Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) from $4 to $2. HC Wainwright &amp; Co. analyst Matthew Caufield downgraded the stock from Buy to Neutral. Unity Biotechnology shares closed at $0.7790 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/UBX/analyst-ratings">view this stock</a>.</li>
<li>JMP Securities cut Churchill Downs Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) price target from $144 to $138. JMP Securities analyst Jordan Bender maintained a Market Outperform rating. Churchill Downs shares closed at $93.24 on Friday. See how other <a href="https://www.benzinga.com/quote/CHDN/analyst-ratings">analysts view this stock</a>.</li>
<li>JMP Securities increased the price target for DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) from $15 to $21. JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating. DBV Technologies shares closed at $8.41 on Friday. <a href="https://www.benzinga.com/quote/DBVT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased the price target for Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from $85 to $100. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar General shares closed at $101.39 on Friday. See how other <a href="https://www.benzinga.com/quote/DG/analyst-ratings">analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) price target from $30 to $14. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $82 to $95. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar Tree shares closed at $88.17 on Friday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim cut Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) price target from $155 to $115. Guggenheim analyst Robert Drbul maintained a Buy rating. Target shares closed at $94.29 on Friday.  <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital cut the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $40 to $18. Chardan Capital analyst Rudy Li maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) price target from $68 to $74. Wells Fargo analyst Tiago Fauth maintained an Overweight rating. PTC Therapeutics shares closed at $45.93 on Friday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PTCT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png" alt="" class="wp-image-928475" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

CHDN

DBVT

DLTR

PDEX

PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday

JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Market Outperform and lowers the price target from $78 to $29.

JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $29

In the last three months, 5 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $36.0, a high estimate of $78.00, and a low estimate of $14.00. This current average has decreased by 24.37% from the previous average price target of $47.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1748350828_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Prothena Corp's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Prothena Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Prothena Corp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Prothena Corp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Prothena Corp</h2>
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
<h3>Prothena Corp: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Prothena Corp's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5556.0% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Prothena Corp's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2128.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Prothena Corp's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -13.02%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Prothena Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Prothena Corp adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts

Prothena shares are trading lower after HC Wainwright & Co. and Chardan Capital cut their respective price targets on the stock.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 500 points on Tuesday.
Shares of PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) fell sharply in today's pre-market trading following weaker-than-expected <a href="https://www.benzinga.com/quote/PDD">first-quarter results.</a>
PDD Holdings posted first-quarter earnings of $1.56 per share, missing market estimates of $2.49 per share. The company's sales came in at $13.18 billion versus expectations of $14.17 billion.
PDD shares dipped 15.2% to $101.11 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 31.6% to $4.50 in pre-market trading after the company disclosed that Phase 3 AFFIRM-AL clinical trial for Birtamimab in patients with AL Amyloidosis did not meet primary endpoint.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) declined 9.8% to $14.29 in pre-market trading after gaining more than 4% on Friday.</li>
<li>EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) shares fell 8.9% to $15.45 in pre-market trading. EHang Holdings posted a first-quarter adjusted loss of 6 cents per share, versus a year-ago loss of 2 cents per share.</li>
<li>Ruanyun Edai Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) shares dipped 8.5% to $12.22 in pre-market trading following a 3% decline on Friday.</li>
<li>Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) fell 6.1% to $6.03 in pre-market trading.</li>
<li>ZEEKR Intelligent Technology Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) fell 5.8% to $27.49 in pre-market trading.</li>
<li>Ascentage Pharma Group Internat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) fell 5.4% to $25.00 in pre-market trading.</li>
<li>H World Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) declined 3.8% to $34.90 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AAPG

HTHT

Citigourp Global Markets 2% Protected Notes Linked To The Djia

RYET

PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 88.9% to $0.76 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock rose 34.55% to $0.88. The market value of their outstanding shares is at $35.4 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock moved upwards by 15.2% to $11.32. The market value of their outstanding shares is at $236.6 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock rose 11.47% to $1.35. The company's market cap stands at $88.8 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares moved upwards by 11.41% to $9.37. The market value of their outstanding shares is at $256.2 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares moved upwards by 11.25% to $4.44. The company's market cap stands at $292.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) stock decreased by 62.5% to $2.35 during Tuesday's pre-market session. The company's market cap stands at $253.1 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares decreased by 31.03% to $0.8. The market value of their outstanding shares is at $14.0 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) stock decreased by 26.9% to $4.81. The market value of their outstanding shares is at $258.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 20.15% to $447.17. The company's market cap stands at $5.8 billion. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares decreased by 13.07% to $4.59. The company's market cap stands at $125.2 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock declined by 10.97% to $0.21. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRNS

BSGM

IOBT

NVCT

STIM

VTAK

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and lowers the price target from $40 to $18.

Chardan Capital Maintains Buy on Prothena Corp, Lowers Price Target to $18

Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45595440/prothena-announces-phase-3-affirm-al-clinical-trial-for-birtamimab-in-patients-with-al-amyloidosis" rel="noreferrer noopener">amyloidosis on Friday</a>.
AL (amyloid light-chain) amyloidosis is&nbsp;a systemic disease where abnormal proteins, called amyloid fibrils, accumulate in various organs.&nbsp;It&#8217;s the most common <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">type of systemic amyloidosis</a>.
The Phase 3 AFFIRM-AL trial enrolled 207 newly diagnosed patients. Birtamimab was given to the active arm every 28 days at a dose level of 24 mg/kg (maximum dose not to exceed 2500 mg).
Patients in both the active and control arms received a bortezomib-containing chemotherapy regimen as the standard of care, and the use of daratumumab was allowed.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42597251/roche-prothena-partnered-mid-stage-parkinsons-trial-misses-primary-endpoint-but-cling-on-signs-of-clinical-benefits" rel="noreferrer noopener">Roche-Prothena Partnered Mid-Stage Parkinson&#8217;s Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits</a>
The trial did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based on these results, the company will discontinue the development of birtamimab, including stopping the open-label extension of the AFFIRM-AL clinical trial.
&#8220;This is not the outcome that we expected, and we are surprised and disappointed by these results&#8230;,&#8221; said Gene Kinney, President and Chief Executive Officer, Prothena. &#8220;With these results, we believe that the most appropriate action is to discontinue all development of birtamimab.&#8221;
In the Phase 3 AFFIRM-AL clinical trial, the primary endpoint of time to all-cause mortality was not met for patients treated with birtamimab.
In addition, neither of the secondary endpoints: 6-minute walk test distance (nominal p-value=0.5288) and Short Form-36 version 2 Physical Component Score (nominal p-value=0.9597).
Birtamimab was generally safe and well-tolerated, consistent with its established safety profile.
&#8220;While we are all disappointed with today&#8217;s results, Prothena has meaningful data readouts and pipeline updates over the next 18 months,&#8221; said Daniel G. Welch, Chair of Prothena&#8217;s Board of Directors.
&#8220;We look forward to initial data from the Phase 1 ASCENT clinical trials on PRX012 in Alzheimer&#8217;s disease expected in August, and program updates from our partners at Roche expected mid-year, Novo Nordisk expected in 2H25, and Bristol Myers Squibb expected in 2026. The company and board have begun the work to thoughtfully and expeditiously decrease spend, including but not limited to an expected substantial workforce reduction, and evaluate with its financial advisors business options in the best interest of its shareholders.&#8221;
In June, the company expects to provide details of plans to reduce ongoing operating expenses. Once the analysis and plans are finalized, the company will communicate the results of reviewing its business options as appropriate.
Price Action: At the last check on Tuesday, PRTA stock was down 26.80% at $4.82 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45614146/weride-stock-is-soaring-tuesday-whats-driving-the-action" target="_blank" rel="noreferrer noopener">WeRide Stock Is Soaring Tuesday: What&#8217;s Driving The Action?</a></li>
</ul>

Biotech

Health Care

General

Why Is Prothena Stock Trading Lower On Tuesday?

HC Wainwright &amp; Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and lowers the price target from $30 to $14.

HC Wainwright & Co. Maintains Buy on Prothena Corp, Lowers Price Target to $14

U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of major benchmark indices were trading higher in premarket.
The markets were closed on Monday in observance of <a href="https://www.benzinga.com/markets/25/05/45605452/is-the-stock-market-open-on-memorial-day-heres-whats-open-and-closed-on-may-26">Memorial Day</a> holiday, affecting trading activity in the exchanges, including the New York Stock Exchange and Nasdaq.
President Donald Trump announced the <a href="https://www.benzinga.com/25/05/45603240/trump-agrees-to-extend-50-tariffs-on-europe-until-july-9-it-was-my-privilege-to-do-so">extension of the 50% tariffs</a> on Sunday till July 9, which he had initially announced on Friday.
Trump said that he spoke to European Commission President Ursula von der Leyen, who said in a post on X that the EU is ready to engage in swift and decisive negotiations.
Meanwhile, the 10-year Treasury bond yielded 4.46% and the two-year bond was at 3.98%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 97.9% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.29%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.50%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.72%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.66%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Tuesday. The SPY was up 1.54% to $588.01, while the QQQ advanced 1.73% to $518.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Sectoral moves weighed on U.S. stocks Friday, with information technology, consumer discretionary, and communication services contributing to the S&amp;P 500&#8217;s fourth consecutive daily decline.
However, consumer staples and utilities bucked the trend to close higher.
Individual stock movements reflected broader concerns: Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares dropped nearly 3% after President Trump demanded domestic iPhone manufacturing, threatening a 25% tariff.
Ross Stores Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) plunged about 10% on weaker-than-expected second quarter EPS guidance, while Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) sank 20% following its fourth quarter earnings report.
Meanwhile, U.S. sales of new single-family homes surprisingly climbed 10.9% month-over-month to an annualized rate of 743,000 units.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.00%</td>
<td>18,737.21</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.67%</td>
<td>5,802.82</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.61%</td>
<td>41,603.07</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.28%</td>
<td>2,039.85</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Billionaire investor Chamath Palihapitiya signaled a<a href="https://www.benzinga.com/markets/25/05/45610672/market-is-risk-off-chamath-palihapitiya-flags-rising-investor-fear-as-money-market-fund-assets-hit-724-trillion"> significant shift in market sentiment</a>, highlighting a new trend. 
On Monday, he posted on X, declaring the &#8220;market is risk-off,&#8221; citing a Barchart post that revealed money market fund assets surged to a new all-time high of $7.24 trillion.
This preference for money market funds, or cash equivalents, typically intensifies during periods of heightened market and economic turmoil.
The recent spike underscores growing investor caution amid persistent macroeconomic uncertainty and evolving interest rate expectations, indicating a major swing in investor confidence over the past couple of weeks.
Chamath, in his post, implied that the investors were fleeing riskier assets such as stocks in favor of safer, yield-generating instruments.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Market is risk-off. <a href="https://t.co/JkULbZlO1u">https://t.co/JkULbZlO1u</a>
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1927137685799321637?ref_src=twsrc%5Etfw">May 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
While some view this as investor anxiety, others, like The Market Ear, see these funds as &#8220;dry powder,&#8221; which means the cash reserves poised to re-enter the market once a clear positive signal emerges.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Now that&#39;s some dry powder! $7 trillion sitting in U.S. money market funds. <a href="https://t.co/xT7nEMBV52">pic.twitter.com/xT7nEMBV52</a>
&mdash; The Market Ear (@themarketear) <a href="https://twitter.com/themarketear/status/1926948542825771487?ref_src=twsrc%5Etfw">May 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ed Yardeni hinted that the week ahead would be crucial for bond investors as the &#8220;One Big Beautiful Bill,&#8221; reaches the Senate for discussions.
&#8220;And in the aftermath of Moody&#8217;s downgrading the US to &#8220;Aaa&#8221; on May 16, financial markets will pay close attention to events on Capitol Hill. Namely, how the deficit-bloating &#8220;Big, Beautiful Bill&#8221; that the House passed last week lands with Senate Republicans, as well as the Bond Vigilantes,&#8221; he said.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul class="wp-block-list">
<li>On Tuesday, Minneapolis Fed President Neel Kashkari will speak in Tokyo at 4:00 a.m. ET.</li>
<li>April&#8217;s durable goods orders data will be released by 8:30 a.m., and March&#8217;s S&amp;P CoreLogic Case-Shiller home price index data for 20 cities will be announced by 9:00 a.m. ET.</li>
<li>May&#8217;s consumer confidence data will be out by 10:00 a.m. and New York Fed President John Williams will speak in Tokyo at 8:00 p.m. ET.</li>
<li>On Wednesday, Minneapolis Fed President Neel Kashkari will speak in Tokyo again at 4:00 a.m., and minutes of the Fed&#8217;s May FOMC meeting will be out by 2:00 p.m. ET.</li>
<li>On Thursday, the initial jobless claims for the week ending May 24 and the first quarter revised GDP data will be out by 8:30 a.m. ET.</li>
<li>Richmond Fed President Tom Barkin will speak at 8:30 a.m. ET.</li>
<li>Pending home sales data for April will be released by 10:00 a.m. ET.</li>
<li>Chicago Fed President Austan Goolsbee will speak at 10:40 a.m., Fed Governor Adriana Kugler will speak at 2:00 p.m., San Francisco Fed President Mary Daly will speak at 4:00 p.m., and Dallas Fed President Lorie Logan will speak at 8:45 p.m. ET.</li>
<li>On Friday, April&#8217;s headline and core PCE, personal income, and consumer spending will be out by 8:30 a.m. ET.</li>
<li>April&#8217;s advanced U.S. trade balance in goods, advanced retail inventories, and advanced wholesale inventories data will be announced by 8:30 a.m. ET, as well.</li>
<li>May&#8217;s Chicago Business Barometer (PMI) will be released at 9:45 a.m., final consumer sentiment data for May will be out by 10:00 a.m., and San Francisco Fed President Mary Daly will speak at 4:45 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>AutoZone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) rose 1.61% in premarket on Tuesday as analysts expect it to report quarterly earnings of $37.03 per share on revenue of $4.35 billion, before the opening bell.</li>
<li>Bank of Nova Scotia. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNS#NYSE">BNS</a>) advanced 0.48% as analysts expect it to report quarterly earnings of $1.17 per share on revenue of $6.36 billion, before the opening bell.</li>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) jumped 1.16% after announcing that it filed a prospectus supplement to increase the shares offered under its sales agreement to be worth $2.51 million.</li>
<li>Heico Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) was up 0.40% as analysts expect it to report quarterly earnings of $1.03 per share on revenue of $1.06 billion, after the closing bell.</li>
<li>Okta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) was 2.57% higher as analysts expect it to report quarterly earnings of 77 cents per share on revenue of $680.32 million, after the closing bell.</li>
<li>Diginex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) surged 22.79% after the company announced the signing of a Memorandum of Understanding for an all-share acquisition of Matter DK ApS.</li>
<li>Digital Ally Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) zoomed 17.20% after it announced a 1-for-100 reverse stock split last week.</li>
<li>Prothena Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) slumped 28.57% after the company disclosed that the Phase 3 AFFIRM-AL clinical trial for Birtamimab in patients with AL Amyloidosis did not meet the primary endpoint.</li>
<li>Imunon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) plummeted 29.59% after the company reported up to $9.75 million private placement priced at the market under Nasdaq rules.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.24% to hover around $61.69 per barrel.
Gold Spot US Dollar fell 1.32% to hover around $3,298.74 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.42% at the 99.3510 level.
Asian markets were mixed on Tuesday as South Korea's Kospi, China&#8217;s CSI 300, and India's S&amp;P BSE Sensex indices declined, whereas Japan's Nikkei 225, Australia's ASX 200, and Hong Kong's Hang Seng indices rose. European markets were higher in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45611941/quantum-computing-stocks-in-focus-pure-play-vs-large-caps-heres-a-look-at-the-valuations">Quantum Computing Stocks In Focus: Pure Play Vs. Large Caps &#8211; Here&#8217;s A Look At The Valuations </a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Equities

Market Summary

Futures

Economics

AAPL

DECK

ROST

US Stocks Likely To Open Higher After S&P 500's Four-Day Fall: 'Market Is Risk-Off,' Says Expert

Press Releases

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Announces Board of Directors Update

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Comments

Prothena Corp

Prothena Corp (PRTA) Opciones

Prothena Corp (NASDAQ:PRTA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL